Enlighten Study: The EV-ICD Post Approval Registry
← catalyst calendarNCT06048731 · readout in 1,380 d
Sponsored by Medtronic (industry) · MDT — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
131
Countries
Austria, Belgium, Canada +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-01 | actual | When the study began enrolling |
| Primary completion | 2030-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2037-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ventricular Arrhythmia
- Tachycardia
Intervention
- Device: Defibrillation using EV-ICD
Primary outcome
what the primary-completion date above is the date OFComplication-free survival rate
measured 5 years
Publications
- PMID 40224263 — linked by the registry
- PMID 40172499 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · MDT's whole pipeline · Catalyst calendar · Every registered study · What changed